0.05Open0.05Pre Close0 Volume1.29K Open Interest4.50Strike Price0.00Turnover640.73%IV1156.91%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier25DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.2589Delta0.5286Gamma7.26Leverage Ratio-0.0039Theta0.0000Rho1.88Eff Leverage0.0003Vega
Relmada Therapeutics Stock Discussion
Dow Jones· 5 mins ago
Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017
Relmada Therapeutics has Commenced a Process to Explore Strategic Alternatives to Maximize Shareholder Value
Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial Is Futile at Its Interim Analysis and Is Unlikely to Meet the Primary Efficacy Endpoint With Statistical Significance
No comment yet